Savant Capital LLC Sells 88,315 Shares of Organon & Co. (NYSE:OGN)

Savant Capital LLC lessened its stake in shares of Organon & Co. (NYSE:OGN - Free Report) by 83.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 18,017 shares of the company's stock after selling 88,315 shares during the period. Savant Capital LLC's holdings in Organon & Co. were worth $269,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in OGN. Blue Trust Inc. raised its position in shares of Organon & Co. by 217.5% during the 3rd quarter. Blue Trust Inc. now owns 3,661 shares of the company's stock valued at $76,000 after buying an additional 2,508 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of Organon & Co. by 6.2% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 261,191 shares of the company's stock valued at $4,997,000 after buying an additional 15,187 shares in the last quarter. Sequoia Financial Advisors LLC raised its position in shares of Organon & Co. by 137.4% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 28,776 shares of the company's stock valued at $550,000 after buying an additional 16,657 shares in the last quarter. Eastern Bank purchased a new stake in shares of Organon & Co. during the 3rd quarter valued at about $55,000. Finally, Lecap Asset Management Ltd. raised its position in shares of Organon & Co. by 23.2% during the 3rd quarter. Lecap Asset Management Ltd. now owns 15,565 shares of the company's stock valued at $298,000 after buying an additional 2,934 shares in the last quarter. 77.43% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on OGN shares. Morgan Stanley reduced their price objective on shares of Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating on the stock in a research report on Friday, February 14th. TD Cowen raised shares of Organon & Co. to a "hold" rating in a research report on Wednesday, January 15th. Finally, Barclays reduced their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. One analyst has rated the stock with a sell rating, three have given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $20.80.

Organon & Co. Trading Down 1.4 %

Shares of NYSE:OGN traded down $0.23 during trading on Friday, reaching $15.47. 3,552,612 shares of the company were exchanged, compared to its average volume of 2,857,279. The firm has a market capitalization of $3.98 billion, a PE ratio of 4.64, a P/E/G ratio of 0.85 and a beta of 0.76. The business's fifty day simple moving average is $15.36 and its 200-day simple moving average is $17.31. Organon & Co. has a 12-month low of $13.87 and a 12-month high of $23.10. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21.

Organon & Co. (NYSE:OGN - Get Free Report) last issued its earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.09). The company had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. On average, research analysts anticipate that Organon & Co. will post 3.78 EPS for the current year.

Organon & Co. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 13th. Stockholders of record on Monday, February 24th will be given a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.24%. The ex-dividend date is Monday, February 24th. Organon & Co.'s dividend payout ratio (DPR) is presently 33.63%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.